Eton Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$16.99
−$0.26 (−1.50%) 4:00 PM ET
After hours$16.80
−$0.19 (−1.12%) 8:00 PM ET
Prev closePrevC$17.25
OpenOpen$17.03
Day highHigh$17.34
Day lowLow$16.86
VolumeVol223,148
Avg volAvgVol274,703
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$455.63M
P/E ratio
-65.35
FY Revenue
$70.32M
EPS
-0.26
Gross Margin
51.36%
Sector
Healthcare
AI report sections
BEARISH
ETON
Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals shows solid top-line expansion and positive free cash flow despite reporting a net loss, while valuation multiples appear elevated relative to current profitability. Recent price action is tilted bullish with momentum indicators and multiple breakout signals, yet medium-term returns remain slightly negative and short interest and short-volume metrics point to notable skepticism and potential volatility. The balance sheet offers adequate liquidity but meaningful leverage, which, combined with high EV/EBITDA and negative ROE, underscores execution and valuation risk if growth or margins weaken.
AI summarized at 1:09 PM ET, 2026-02-12
AI summary scores
INTRADAY:63SWING:58LONG:46
Volume vs average
Intraday (cumulative)
−30% (Below avg)
Vol/Avg: 0.70×
RSI
57.71(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
-0.01 (Weak)
MACD: 0.01 Signal: 0.02
Short-Term
+0.17 (Strong)
MACD: 0.63 Signal: 0.46
Long-Term
+0.24 (Strong)
MACD: 0.55 Signal: 0.31
Intraday trend score
34.82
LOW34.82HIGH48.82
Latest news
ETON•12 articles•Positive: 1Neutral: 0Negative: 0
PositiveGlobeNewswire Inc.• Na
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
Eton Pharmaceuticals announced FDA approval of DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus treatment. The product, launching March 9th, is the first FDA-approved oral liquid formulation enabling precise dosing without tablet splitting. Eton projects peak annual sales of $30-50 million with patent protection through 2044, targeting over 13,000 U.S. patients including 3,000-4,000 pediatric patients.
FDA approval of a first-in-class product with significant commercial potential ($30-50M peak sales), long patent protection through 2044, addresses unmet clinical needs in rare disease treatment, and leverages existing commercial infrastructure for market penetration.
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400• Management to hold conference call today at 4:30pm ET
ETONEarnings Releases and Operating Results
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:
ETONCalendar of Events
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 -
ETONHealthPatentsProduct / Services Announcement
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
ETONConference Calls/ Webcasts
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. rights to PKU GOLIKE® from RELIEF THERAPEUTICS Holding SA (“Relief”) (SIX: RLF, OTCQB: RLFTF, RLFTY).
ETONMergers and Acquisitions
UnknownZacks Investment Research• Zacks Equity Research
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates
Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ETONLVTX
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter and year ended December 31, 2023.
ETONEarnings Releases and Operating Results
UnknownZacks Investment Research• Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CRDFETON
UnknownGlobeNewswire Inc.• Eton Pharmaceuticals
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).
ETONCalendar of EventsConference Calls/ Webcasts
UnknownZacks Investment Research• Zacks Equity Research
Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
IOVAETON
UnknownZacks Investment Research• Zacks Equity Research
Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?
Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.
SRPTCGENETONARQT
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
